We recently published an article titled The 10 Best Long-Term Healthcare Stocks to Buy.

On January 9, UBS upgraded Oscar Health, Inc. (NYSE:OSCR) to Neutral from Sell and raised its price target to $17 from $12. The company cited better-than-expected exchange enrollment trends despite the expiration of enhanced subsidies and noted that the stock appears fairly valued at current levels.

In the third quarter of 2025, Oscar Health, Inc. (NYSE:OSCR) reported a 23% year-over-year increase in total revenue to approximately $3 billion. The medical loss ratio increased 380 basis points to 88.5%, reflecting cost pressures during the period. The company also laid out plans to expand to 20 states by 2026, including new entries in Alabama and Mississippi, while launching additional products like HelloMeno. Management highlighted ongoing investments in technology, including the integration of AI tools through its Oswell platform, with the aim of improving operational efficiency and member engagement.

Oscar Health, Inc. (NYSE:OSCR) was founded in 2012 as a technology-focused health insurance company. The company seeks to improve access and affordability through digital tools, virtual care and data-driven plan design.

While we recognize OSCR’s potential as a long-term investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 8 Emerging streaming companies and services i 9 High Growth Canadian Stocks to Buy

Disclosure: no.